Aptus Pharma
251.35
-251.35(-100.00%)
Market Cap₹172.40 Cr
PE Ratio-
Company Performance:
1D-100.00%
1M-100.00%
6M-100.00%
1Y-100.00%
5Y-100.00%
View Company Insightsright
More news about Aptus Pharma
12Dec 25
Aptus Pharma Expands OTC Business in Gujarat Market
Aptus Pharma Limited is expanding its over-the-counter (OTC) business in Gujarat through its AptusWellCare Division. The expansion focuses on face care, body care, and hair care products, leveraging brands like Timglo, Kerava, and Shirovita. The company plans to enhance its product portfolio, including upcoming launches in hygiene care, pain relief, and oral care. To support this growth, Aptus Pharma is strengthening its field force and expanding its distributor network across Gujarat.
 no imag found
11Dec 25
Trump Says Apple CEO Discussed Hiring Difficulties in Recent Conversation
Trump disclosed that Apple's CEO shared concerns about hiring difficulties during a recent conversation. The discussion highlighted ongoing recruitment challenges facing the technology sector. This revelation provides insight into current workforce acquisition difficulties experienced by major technology corporations.
 no imag found
21Nov 25
Aptus Pharma Limited Expands into Urology Therapy Segment
Aptus Pharma Limited announces strategic expansion into the urology therapy segment. The company plans to launch multiple products, including Solifenacin Succinate Tablets for overactive bladder and Tamsulosin Hydrochloride Capsules for benign prostatic hyperplasia, subject to regulatory approvals. This move targets the growing global urology devices market, projected to reach $62.76 billion by 2028. The company aims to leverage its existing distribution network and manufacturing capabilities, while exploring partnerships to support growth in this new segment.
 no imag found
11Nov 25
Aptus Pharma Limited Reports Robust 47% Revenue Growth in H1
Aptus Pharma Limited announced robust financial results for H1 FY24. Total revenue increased by 47.38% to Rs. 1,437.75 lakhs, EBITDA grew by 36.12% to Rs. 294.55 lakhs, and PAT rose by 33.81% to Rs. 174.69 lakhs compared to the previous year. The company experienced slight margin compression with EBITDA margin at 20.49% and PAT margin at 12.15%. Growth was attributed to product portfolio expansion, strengthened marketing network, and improved operational efficiency. The company plans to continue investing in new products, digital initiatives, and distribution expansion.
 no imag found
Aptus Pharma
251.35
-251.35
(-100.00%)
1 Year Returns:-100.00%
Industry Peers
LG Electronics
1,549.10
(+0.08%)
Voltas
1,546.90
(+2.26%)
Blue Star
1,968.40
(-0.04%)
Amber Enterprises
7,650.50
(-0.71%)
Crompton Greaves
265.43
(-0.18%)
V-Guard Industries
315.40
(-2.28%)
Whirlpool
930.25
(+1.82%)
Eureka Forbes
514.55
(+0.50%)
TTK Prestige
534.35
(-3.25%)
Symphony
829.25
(+0.59%)